Open label evaluation of cannabidiol in dystonic movement disorders

Int J Neurosci. 1986 Nov;30(4):277-82. doi: 10.3109/00207458608985678.


Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Cannabidiol / adverse effects
  • Cannabidiol / therapeutic use*
  • Cannabinoids / therapeutic use*
  • Dystonia / chemically induced
  • Dystonia / drug therapy*
  • Dystonia Musculorum Deformans / drug therapy
  • Female
  • Humans
  • Levodopa / adverse effects
  • Male
  • Meige Syndrome / drug therapy
  • Middle Aged
  • Muscle Spasticity / drug therapy
  • Torticollis / drug therapy


  • Cannabinoids
  • Cannabidiol
  • Levodopa